๐๐ง๐ฅ๐จ๐๐ค๐ข๐ง๐ ๐๐ซ๐จ๐ฐ๐ญ๐ก: ๐๐ฎ๐ซ ๐๐ก๐๐ฌ๐ข๐ฌ ๐จ๐ง ๐ญ๐ก๐ ๐๐ข๐๐๐ฅ๐ ๐๐๐ฌ๐ญ, ๐๐ง๐๐ข๐ ๐๐ง๐ ๐๐ ๐๐ฌ๐ข๐ ๐๐ฌ ๐ฆ๐๐ฌ๐ฌ๐ข๐ฏ๐ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก ๐จ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐ข๐ง ๐ก๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐ง๐ ๐ฅ๐ข๐๐ ๐ฌ๐๐ข๐๐ง๐๐๐ฌ
At Atelier Health, weโve spent the past year immersing ourselves in the vibrant healthcare and life sciences ecosystems of the Middle East, India, and Southeast Asia. Through hundreds of candid conversations with executives, venture funds, and private equity leaders, and by evaluating countless businesses with our proprietary AI platform, Wayfinder, weโve crafted a unique perspective on these dynamic markets. Our thesis? These regions both high growth and high potential, poised to redefine global healthcare. Here are three bespoke insights fueling our excitement.
๐๐ก๐๐ฌ๐ข๐ฌ 1: ๐๐๐๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐๐ฌ ๐ญ๐ก๐ ๐๐ซ๐๐๐ญ ๐๐ช๐ฎ๐๐ฅ๐ข๐ณ๐๐ซ
Imagine a world where 3 billion people access diagnostics or triage with a tap on their phone. Thatโs todayโs reality in these regions, where technology is shattering barriers to care. Wayfinder reveals AI-driven solutions slashing costs to a fraction of developed-world prices. Local innovators arenโt just serving their communitiesโtheyโre building scalable models ready to disrupt markets like the US. Weโve seen it firsthand: these are the future global leaders of healthtech.
๐๐ก๐๐ฌ๐ข๐ฌ 2: ๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐๐ฐ ๐๐จ๐ง๐ฌ๐ฎ๐ฆ๐๐ซ๐ฌ, ๐ ๐๐๐ฐ ๐๐๐ซ๐ ๐๐๐ซ๐๐๐ข๐ ๐ฆ
Over 1 billion people have risen into affluence across these regions, craving modern healthcare. But the infrastructure? Itโs playing catch-up. Top-tier hospitals shine, yet lifestyle medicine, home health, and specialty care lag behind. Our dialogues with industry leaders highlight a hunger for solutions that blend innovation with accessibility. Wayfinderโs insights show us where to bridge this gap, crafting businesses that meet this surging demand with precision and heart.
๐๐ก๐๐ฌ๐ข๐ฌ 3: ๐๐ก๐ ๐๐๐ซ๐ฅ๐ฒ-๐๐ญ๐๐ ๐ ๐๐ง๐ฏ๐๐ฌ๐ญ๐ฆ๐๐ง๐ญ ๐
๐ซ๐จ๐ง๐ญ๐ข๐๐ซ
Late-stage investors in MENA, India, and Southeast Asia have struck gold in inpatient care, with the regionโs healthcare market set to grow at 11.7% annually through 2027. But the real opportunity lies earlier. From incubation to Series A, healthtech and life sciences ventures are brimming with potential yet starved for capital. Our client engagements uncovered this gap, and we will continue to guide family offices and corporates to fuel these game-changers from the ground up.
At Atelier Health, our goal is to help our clients invest in and launch sustainable, transformative businesses that can impact the lives of billions of people. These markets pulse with that possibility, and weโre ready to help. Whatโs the boldest healthcare vision you see for these regions?
Duis ultricies mi sed lorem blandit, non sodales sapien fermentum. Donec ultricies, turpis a sagittis suscipit, ex odio volutpat sem, vel molestie ligula enim varius est.Duis ultricies mi sed lorem blandit, non sodales sapien fermentum. Donec ultricies, turpis a sagittis suscipit, ex odio volutpat sem, vel molestie ligula enim varius est.Purus in massa tempor nec feugiat nisl pretium fusce. Purus in massa tempor nec feugiat nisl pretium fusce. Mollis aliquam ut porttitor leo. Sapien pellentesque habitant morbi tristique senectus et netus et malesuada. Dolor sit amet consectetur adipiscing elit duis. Blandit libero volutpat sed cras ornare arcu dui vivamus arcu. Lorem mollis aliquam ut porttitor leo a. Scelerisque purus semper eget duis at tellus. Pharetra vel turpis nunc eget lorem dolor sed. Enim diam vulputate ut pharetra sit amet aliquam id diam. Pretium viverra suspendisse potenti nullam ac tortor vitae purus faucibus. Facilisi cras fermentum odio eu feugiat. Tristique senectus et netus et malesuada fames ac, urpis in eu mi pellentesque habitant morbi tristique senectus et netus et malesuada susi amn bibendum.
Related Posts
๐๐๐ฉ๐ข๐ ๐๐ข๐ซ๐ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐ง ๐๐ข๐ง๐๐ฒ ๐๐ซ๐๐ฌ๐๐’๐ฌ ๐๐๐ฉ๐๐ซ๐ญ๐ฎ๐ซ๐ ๐๐ซ๐จ๐ฆ ๐ญ๐ก๐ ๐ ๐๐:
The recent departure of Vinay Prasad from the FDA, following controversy over Sarepta Therapeuticsโ gene therapy Elevidys, underscores the complex risks that family offices can face when making mission driven biopharma investments. Prasad, a vocal critic of accelerated approvals, left the FDA after spearheading a crackdown on Elevidys, prompted by three patie
๐๐ก๐๐ญ’๐ฌ ๐ข๐ง ๐ ๐ง๐๐ฆ๐: ๐๐ก๐ ๐ฌ๐ญ๐จ๐ซ๐ฒ ๐๐๐ก๐ข๐ง๐ ๐ฐ๐ก๐ฒ ๐ฐ๐ ๐๐ซ๐ ๐๐๐ฅ๐ฅ๐๐ ๐๐ญ๐๐ฅ๐ข๐๐ซ ๐๐๐๐ฅ๐ญ๐ก
Introducing Atelier Health (…and what we’ve been up to)
The global healthcare and life sciences sectors are at an inflection point, particularly in the rapidly evolving markets of the Middle East, India, and Southeast Asia.